Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

The dramatic increase in the prevalence and clinical impact of infections caused by bacteria
producing carbapenemases is a global health concern. Carbapenemase production is …

Abstract Objective Ceftazidime–avibactam (CAZ-AVI) is a novel synthetic β-lactamase
inhibitor combination. Although the combination has been available clinically for only a few …

β-Lactamases, the enzymes that hydrolyze β-lactam antibiotics, remain the greatest threat to
the usage of these agents. In this review, the mechanism of hydrolysis is discussed for both …

Background Carbapenem resistance is defined as in vitro non-susceptibility to any
carbapenem and/or documented production of a carbapenemase. This feature has rapidly …

Septicaemia likely results in high case-fatality rates in the present multidrug-resistant (MDR)
era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated …

Highlights•Carbapenem-resistant Gram-negative pathogens are a priority for R&D,
according to WHO.•Increasing need for new therapies against Klebsiella, Pseudomonas and …

Background Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-
KP) has become one of the most important contemporary pathogens, especially in endemic …

Carbapenem-sparing strategies should be used, when feasible, for ESBL infections. The
majority of available nonrandomized studies highlight that combination for CRE seem to …

The pharmacokinetic (PK) and pharmacodynamic (PD) parameters which correlated with the
in vivo efficacy of cefiderocol were evaluated using neutropenic murine thigh and lung …